Skip to main content

Table 2 Univariate Logistic regression analysis for risk factors with post-thrombolysis END and post-thrombolysis ENI

From: The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke

Variable Crude model for post-thrombolysis END Crude model for post-thrombolysis ENI
OR (95%CI) P OR (95%CI) P
Demographic characteristics
 Age 1.033 (1.018–1.048) 0.001 0.982 (0.972–0.993) 0.002
 Male 0.813 (0.587–1.125) 0.211 0.950 (0.729–1.237) 0.702
 BMI 1.032 (0.987–1.079) 0.169 0.974 (0.940–1.010) 0.159
Vascular risk factors
 Hypertension 1.033 (0.737–1.447) 0.851 1.070 (0.819–1.399) 0.629
 Diabetes mellitus 1.254 (0.877–1.794) 0.215 0.711 (0.524–0.964) 0.028
 Dyslipidemia 0.972 (0.682–1.383) 0.873 1.153 (0.872–1.523) 0.317
 Atrial fibrillation 1.385 (0.962–1.995) 0.080 0.828 (0.606–1.130) 0.235
 Current smoking 0.933 (0.665–1.308) 0.687 1.047 (0.802–1.366) 0.737
 Current drinking 1.204 (0.868–1.671) 0.226 1.004 (0.770–1.309) 0.977
 Previous stroke 0.847 (0.574–1.249) 0.402 0.848 (0.625–1.150) 0.288
 Peripheral artery disease 0.813 (0.419–1.577) 0.540 1.235 (0.758–2.012) 0.397
 Coronary artery disease 1.049 (0.708–1.555) 0.810 1.140 (0.833–1.561) 0.412
Medication use history
 Previous antiplatelet 0.469 (0.290–0.760) 0.002 1.504 (1.102–2.053) 0.010
 Previous anticoagulation 1.415 (0.512–3.909) 0.504 0.514 (0.187–1.413) 0.197
 Previous statin 0.848 (0.638–1.127) 0.256 1.050 (0.855–1.289) 0.642
Clinical assessment
 NIHSS 1.051 (1.030–1.072) 0.001 1.007 (0.990–1.024) 0.446
 SBP 0.995 (0.989–1.002) 0.195 0.998 (0.993–1.002) 0.359
 DBP 0.998 (0.993–1.009) 0.737 0.990 (0.982–0.999) 0.023
 HT 3.248 (2.020–5.221) 0.001 0.290 (0.158–0.532) 0.001
 OTT 1.004 (1.001–1.006) 0.011 0.993 (0.990–0.995) 0.001
 PAO 1.894 (1.368–2.623) 0.001 0.634 (0.476–0.843) 0.002
 Endovascular treatment 1.464 (0.997–2.148) 0.052 0.882 (0.633–1.228) 0.456
Stroke subtype
 LAA Reference   Reference  
 CE 1.065 (0.731–1.552) 0.743 1.194 (0.881–1.618) 0.252
 SAO 0.529 (0.329–0.849) 0.008 0.828 (0.592–1.157) 0.268
 SOE 1.443 (0.623–3.341) 0.392 0.549 (0.240–1.253) 0.154
 SUE 1.844 (1.063–3.197) 0.029 0.941 (0.566–1.563) 0.813
Lesion location
 Anterior circulation Reference   Reference  
 Posterior circulation 0.890 (0.615–1.288) 0.537 1.147 (0.861–1.528) 0.347
Laboratory data
 TC 1.003 (0.996–1.010) 0.447 0.999 (0.994–1.003) 0.591
 TG 1.000 (0.998–1.002) 0.623 1.001 (0.996–1.005) 0.655
 HDL 1.255 (0.953–1.654) 0.106 0.889 (0.664–1.190) 0.428
 LDL 0.999 (0.992–1.005) 0.708 1.002 (0.998–1.005) 0.415
 FBG 1.084 (1.032–1.138) 0.002 1.035 (0.991–1.080) 0.119
 Hs-CRP 1.033 (1.018–1.048) 0.001 0.997 (0.984–1.010) 0.630
 NLR 1.661 (1.528–1.807) 0.001 0.678 (0.626–0.735) 0.001
 PLR 1.014 (1.011–1.017) 0.001 0.997 (0.995–0.999) 0.004
 LMR 0.869 (0.758–0.996) 0.043 1.152 (1.033–1.284) 0.011
  1. Abbreviation: END early neurological deterioration, ENI early neurological improvement, OR odds ratio, CI confidence interval, BMI body mass index, NIHSS National Institute of Health Stroke Scale, SBP systolic blood pressure, DBP diastolic blood pressure, HT hemorrhagic transformation, OTT onset to treatment time, PAO proximal arterial occlusion, LAA large-artery atherosclerosis, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other determined etiology, SUE, stroke of undetermined etiology, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, FBG fasting blood glucose, Hs-CRP hyper-sensitive C-reactive protein, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, LMR lymphocyte-monocyte ratio